(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.


Figure 4


Fig. 4. Effects of FGF8 reduction on mesoderm formation. (A-I) X. laevis embryos; all embryos injected into the marginal zone of one cell at the two-cell stage; (F-H,K,L,N,O) pink staining for the fluorescein-conjugated control MO indicates injected side; (B-E,I) red-gal indicates injected side. (A) Control xbra expression; (B) XlMOF8 (40 ng) strongly reduces xbra expression (19/20 embryos), and this loss can be rescued by human FGF8b (13/17), mouse FGF8f (14/20) and Xenopus FGF4 (17/23) (C-E). (F) MOSDF8 (85 ng) reduces xbra expression (27/31 embryos); (G) FGF8b rescues MOSDF8 phenotype (33/40); but FGF8a does not rescue (32/42) (H). (I) MOSAF8a (FGF8a-specific) (60 ng) does not affect xbra expression (15/16). (J-L) X. tropicalis embryos. MOSDF8 (42 ng) reduces xbra expression (22/28) (K). FGF8b rescues MOSDF8 (30/37) (L). (M-O) X. laevis embryos, dorsal views with anterior to the left. (M) Control stage 13 myoD expression. (N) MOSDF8 85 ng (39/39 reduced); (O) XlMOF8 (30 ng) (22/22 reduced).